Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 68Recurrence 17Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Renal Insufficiency 2Plasmacytoma 2Myeloproliferative Disorders 2Chromosome 17 deletion 2Amyloidosis 2Thrombocytosis 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Dexamethasone 10Bortezomib 7Lenalidomide 4isatuximab 3Calcium Dobesilate 3pomalidomide 2Thalidomide 2Gemcitabine 2Cyclophosphamide 2vinflunine 1melflufen 1glucarpidase 1gallium 68 PSMA-11 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Tablets 1Ranitidine 1Pluvicto 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Eplerenone 1Doxorubicin 1Diphenhydramine 1Carboplatin 1Bendamustine Hydrochloride 1BHQ880 1Acetaminophen 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Renal Insufficiency × pomalidomide × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Celgene

Phase 2 Completed
81 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡